维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

5篇 您的检索式：作者名="Naoki Hama"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis显示文摘Background: In general, para-aortic lymph node(LN16) metastasis has been considered as a contraindication for pancreatic resection. However, some pancreatic cancer patients with LN16 metastasis have been reported to survive for longer than expected after pancreatectomy. The purpose of this study was to determine whether pancreatic cancer patients with LN16 metastasis might benefit from surgery.Methods: We retrospectively reviewed 201 consecutive patients with invasive pancreatic ductal adenocarcinoma who underwent surgery at Osaka National Hospital between April 2003 and December 2012.These patients included 22 patients with LN16 metastasis who underwent an extended lymphadenectomy and 25 patients who underwent a palliative surgical biliary and gastric bypass. The clinicopathological data and outcomes were evaluated using univariate and multivariate analyses.Results: The overall survival of the patients with LN16 metastasis was poorer than that of the LN16-negative patients(P = 0.0014). An overall survival analysis of the LN16-positive patients stratified according to the preoperative CA19-9 level showed a significant difference between patients with a low preoperative CA19-9 level(≤360 U/mL) and those with a high preoperative CA19-9 level(>360 U/mL)(P = 0.0301). No significant difference in overall survival of patients was observed between those with LN16 positivity and those who underwent bypass surgery. However, the overall survival of the LN16-positive patients with a CA19-9 level ≤360 U/mL(n = 11) was significantly higher than that of those who underwent bypass surgery(P = 0.0452).Conclusion: Surgical resection and extended lymphadenectomy remains an option for pancreatic cancer patients with LN16-positivity whose CA19-9 level is ≤360 U/mL.	Tadafumi Asaoka Atsushi Miyamoto Sakae Maeda Naoki Hama Masanori Tsujie Masataka Ikeda Mitsugu Sekimoto Shoji Nakamori	2018	Hepatobiliary & Pancreatic Diseases International2018，17，1：	4
	2	Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineeredto express α-gal epitopes, targets pancreatic cancer stem cells显示文摘	Tsukasa Tanida Masahiro Tanemura Eiji Miyoshi Hiroaki Nagano Kenta Furukawa Yuji Nonaka Hirofumi Akita Naoki Hama Hiroshi Wada Koichi Kawamoto Shogo Kobayashi Hidetoshi Eguchi Masaki Mori Yuichiro Doki	2015	International Journal of Oncology2015，，1：	1
	3	A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer显示文摘	Hidetoshi Eguchi Hiroaki Nagano Shogo Kobayashi Koichi Kawamoto Hiroshi Wada Naoki Hama Yoshito Tomimaru Hirofumi Akita Daisuke Sakai Taroh Satoh Toshihiro Kudo Fumiaki Isohashi Masaki Mori Yuichiro Doki	2014	Cancer Chemotherapy and Pharmacology2014，，2：	1
	4	MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-cateninsignaling pathway in pancreatic cancer cells显示文摘	Hiroaki Nagano Yoshito Tomimaru Hidetoshi Eguchi Naoki Hama Hiroshi Wada Koichi Kawamoto Shogo Kobayashi Masaki Mori Yuichiro Doki	2013	International Journal of Oncology2013，，4：	1
	5	The combination of the expression of hexokinase 2 and pyruvate kinaseM2 is a prognostic marker in patients with pancreatic cancer显示文摘	Hisataka Ogawa Hiroaki Nagano Masamitsu Konno Hidetoshi Eguchi Jun Koseki Koichi Kawamoto Naohiro Nishida Hugh Colvin Akira Tomokuni Yoshito Tomimaru Naoki Hama Hiroshi Wada Shigeru Marubashi Shogo Kobayashi Masaki Mori Yuichiro Doki Hideshi Ishii	2015	Molecular and Clinical Oncology2015，，3：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费